That same year, Sara and others published a proof-of-concept test case using organoids derived from metastatic breast cancer patients with the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha(PIK3CA) mutations, assessing treatment with alpelisib (a specific PI3K-α inhibitor) for multiple secondary lesions, providing a new treatment strategy for breast cancer (81). Here, PIK3CA is linked to breast carcinoma.